Cargando…

An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER(+)) Breast Cancer: Effects on Sensitive and Resistant Cell Lines

Around 70–85% of all breast cancer (BC) cases are estrogen receptor-positive (ER(+)). The third generation of aromatase inhibitors (AIs) is the first-line treatment option for these tumors. Despite their therapeutic success, they induce several side effects and resistance, which limits their efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amaral, Cristina, Correia-da-Silva, Georgina, Almeida, Cristina Ferreira, Valente, Maria João, Varela, Carla, Tavares-da-Silva, Elisiário, Vinggaard, Anne Marie, Teixeira, Natércia, Roleira, Fernanda M. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865664/ https://www.ncbi.nlm.nih.gov/pubmed/36677847 http://dx.doi.org/10.3390/molecules28020789

Ejemplares similares

New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death
por: Cepa, Margarida, et al.
Publicado: (2008)

Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment
por: Amaral, Cristina, et al.
Publicado: (2012)

Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors
por: Almeida, Cristina Ferreira, et al.
Publicado: (2023)

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

The Structural Diversity and Biological Activity of Steroid Oximes
por: Gomes, Ana R., et al.
Publicado: (2023)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
por: Bezerra, Patrícia H. A., et al.
Publicado: (2023)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype
por: Almeida, Cristina Ferreira, et al.
Publicado: (2021)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives
por: Peterson, Amity, et al.
Publicado: (2017)

Anti-Inflammatory Effect of Unsaturated Fatty Acids and Ergosta-7,22-dien-3-ol from Marthasterias glacialis: Prevention of CHOP-Mediated ER-Stress and NF-κB Activation
por: Pereira, David M., et al.
Publicado: (2014)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Methylome Variation Predicts Exemestane Resistance in Advanced ER(+) Breast Cancer
por: Liu, Xiao-ran, et al.
Publicado: (2020)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology
por: Jarzabek, Katarzyna, et al.
Publicado: (2013)

The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs
por: Gao, Lanyang, et al.
Publicado: (2019)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
por: Freedman, OC, et al.
Publicado: (2009)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
por: HOLE, STINE, et al.
Publicado: (2015)

Site-Specific Regulation of Sulfatase and Aromatase Pathways for Estrogen Production in Endometriosis
por: Da Costa, Katiane de Almeida, et al.
Publicado: (2022)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

Mechanism of the Third Oxidative Step in the Conversion of Androgens to Estrogens by Cytochrome P450 19A1 Steroid Aromatase
por: Yoshimoto, Francis K., et al.
Publicado: (2014)

Microbial transformation of anti-cancer steroid exemestane and cytotoxicity of its metabolites against cancer cell lines
por: Baydoun, Elias, et al.
Publicado: (2013)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

The Aromatase–Estrogen System in the Testes of Non-Mammalian Vertebrates
por: Rosati, Luigi, et al.
Publicado: (2021)

Palmitic Acid and Ergosta-7,22-dien-3-ol Contribute to the Apoptotic Effect and Cell Cycle Arrest of an Extract from Marthasterias glacialis L. in Neuroblastoma Cells
por: Pereira, David M., et al.
Publicado: (2013)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Dysregulation of estrogen receptor beta (ERβ), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects
por: Crider, Amanda, et al.
Publicado: (2014)

Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
por: Shioi, Yoshihiro, et al.
Publicado: (2014)

Aromatase expression and role of estrogens in male gonad : a review
por: Carreau, Serge, et al.
Publicado: (2003)

Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
por: Althuwaibi, Maha F., et al.
Publicado: (2023)

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial
por: Guerrieri-Gonzaga, Aliana, et al.
Publicado: (2021)

Organizing Effects of Sex Steroids on Brain Aromatase Activity in Quail
por: Cornil, Charlotte A., et al.
Publicado: (2011)

SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer
por: Young, Patricia A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7k1mrur913ds16j834mvnhddab